This registry-based cohort study aimed to assess both the frequency of prescription of concomitant aspirin (ASA) and DOAC therapy as well as its effect on clinical outcomes in patients with AF or VTE.
Study authors assessed the effectiveness and safety of DOACs compared with warfarin in patients with valvular atrial fibrillation.
Study authors assessed the risk of stroke and systemic embolism in patients with atrial fibrillation and heart failure according to HF types.
Researchers sought to assess the incidence of thrombotic complications in the second wave of patients with COVID-19, how many patients had diagnostic imaging for these complications, overall mortality, and then compared these outcomes with the first wave.
Researchers analyze platelet and neutrophil activation in COVID-19 patients and its association with venous thromboembolism.
Applying clinical prediction rules correctly when treating patients with venous thromboembolism in primary care was found to be associated with low failure rate.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Low-intensity warfarin therapy was found to be as effective as standard-intensity I warfarin in lowering the risk for thromboembolism in older patients with nonvalvular atrial fibrillation.
Expert consensus decision pathway for anticoagulant and antiplatelet use in patients with atherosclerotic cardiovascular disease or in those with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention.
